PCI’s Tredegar site is the latest site to offer full Serialization services to global customers

PCI
Pharma Services (PCI) is pleased to announce the installation and validation of
its latest comprehensive Serialization system, located at its manufacturing Center
of Excellence in Tredegar, UK.The investment
demonstrates PCI’s continued investment in and expansion of market-leading
Serialization capabilities. This latest installation increases PCI’s
Serialization capability to support clients in advance of implementation dates for
the European Falsified Medicines Directive (EU FMD), as well as supply for the
US and emerging markets, including countries such as China, Turkey, Brazil,
Saudi Arabia and others.PCI’s system is
compliant to all EU member country requirements for Serialization and
specialized labeling, including application and integration of advanced
Anticounterfeiting technologies.

The
highly flexible technology delivers machine and human-readable coding, tamper
evident solutions and Bollini labeling – which in turn is linked to a case
loading and aggregation station, with a final aggregation station connecting
cases to pallet. PCI is a strong supporter of the advanced use of aggregation
to support product security, realizing the significant benefits in packaging
operations, as well as the broader pharmaceutical supply chain.

PCI’s site
in Tredegar, South Wales, UK already offers excellence in potent manufacturing
services for customers globally, and this new Serialization technology further
strengthens its comprehensive offering. This investment in the Tredegar
facility is part of a significant global initiative to develop the
Serialization services across PCI’s global network, which will ultimately
exceed more than 90 lines.

Commenting on this latest investment, Jim Neville,
Director of Operations, Tredegar, stated: “This
is an important addition to the site’s capabilities. Being able to offer this
fully flexible service and work in partnership with our customers to deliver a
trusted, seamless service is critical, and being ahead of the timelines with
this offering ensures compliance with the EU FMD.”

PCI has been actively Serializing commercial products
for the US, European and international markets for the past six years, and this
investment in the Tredegar capabilities continues to demonstrate PCI’s
market-leading position. The integrated technology strategy enables operators
in all PCI’s global locations to operate the same graphical user interface,
providing a seamless global service.PCI
clients enjoy singular connectivity to all PCI sites through a best-in-class
platform.PCI is dedicated to
maintaining a leadership position at the forefront of the Serialization
initiative and providing clients with an industry-leading customer experience.

The global healthcare industry trusts PCI for the drug
development solutions that increase their products’ speed to market and
opportunities for commercial success. Only PCI brings the proven experience
that comes with more than 50 successful product launches a year and over four
decades in the healthcare business. Leading technology and continued investment
enables us to address global development needs throughout the product life
cycle — from Phase I clinical trials through commercialization and ongoing
supply. Our clients view us as an extension of their business and a
collaborative partner, with the shared goal of improving patients’ lives.For more information, please visit www.pciservices.comor follow us on Twitter at @PCI_Social.

The foundations for protecting human research subjects come from the
ethical principles surrounding the Belmont report : Respect for persons,
beneficence, and justice. The use of human biospecimens in research
supports these principles with legal and ethical regulations - the most
important of which is permission.(1) This permission may come directly
from the donor or granted by others with authorization to protect the
interests of biospecimen donors.More info >>

The World Advanced Therapies & Regenerative
Medicine Congress is an exhibition and conference that has grown to become one
of the best and most established cell and gene events in the world today.
The 2019 edition will be in its 14th year and it continues to grow and attract
a large audience of biotech, pharma, start-ups, investors, research and
technology companies from around the world. The conference and exhibition will
host over 1000 attendees, 250 speakers and 80 exhibition booths. Over 500
different global companies are represented every year at this event. More info >>